Stocks and InvestingStocks and Investing
Tue, March 1, 2022
Mon, February 28, 2022
Sun, February 27, 2022
Fri, February 25, 2022

Kennen MacKay Maintained (AGIO) at Buy with Increased Target to $67 on, Feb 25th, 2022


Published on 2024-10-27 19:50:42 - WOPRAI, Kennen MacKay
  Print publication without navigation


Kennen MacKay of RBC Capital, Maintained "Agios Pharmaceuticals, Inc." (AGIO) at Buy with Increased Target from $61 to $67 on, Feb 25th, 2022.

Kennen has made no other calls on AGIO in the last 4 months.



There are 4 other peers that have a rating on AGIO. Out of the 4 peers that are also analyzing AGIO, 1 agrees with Kennen's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Andrew Berens of "SVB Leerink" Maintained at Hold with Decreased Target to $30 on, Tuesday, February 22nd, 2022


These are the ratings of the 3 analyists that currently disagree with Kennen


  • Michael King of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $96 on, Thursday, February 24th, 2022
  • John Newman of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $44 on, Wednesday, February 16th, 2022
  • Greg Harrison of "B of A Securities" Initiated at Strong Buy and Held Target at $54 on, Friday, December 3rd, 2021